Table 2.
Distant relapse rates in low-risk breast cancer.
| Study | Number of patients | Median age | Genomic assays Low-risk profile |
ET | Distant relapse |
|---|---|---|---|---|---|
|
Tailor Rx NEJM 2015, 2018 |
1626 | 58 years | Oncotype RS < 11 | Yes | FFDR rate 99.3% @ 5 years and 96.8% @ 9 years |
|
MINDACT study JCO 2022 |
741 | 55 years | MammaPrint ultralow risk/clinical low risk |
No Yes |
DMFI rate 97.8% @ 8 years DMFI rate 97.4% @ 8 years |
|
RASTER Study Eur. J. Cancer; 2022 |
140 | 50 years | MammaPrint low- risk/clinical low-risk | No |
DRFI rate @ 10 years is 93.9% |
|
Clalit Health Services Registry npj Breast Cancer 2017 |
381 | ≥ 70 years | Oncotype RS < 18 | Yes |
KM estimates DR rate @ 10 years is 0.6% |
FFDR Freedom from recurrence at distant site, DMFI distant metastases-free interval, DRFI distant recurrence-free interval, KM Kaplan Meier, DR distant relapse.